Schrodinger Financials - Benzinga

Schrodinger Inc

SDGRNASDAQ

Trade with Public

Trade with Public

$29.48

0.632.17%

Últ. Act.: Sep 28, 1:34 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Schrodinger Financials

Schrodinger (SDGR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Schrodinger Sees FY Drug Discovery Revenue At $65M-$75M

Schrodinger (NASDAQ:SDGR) Sees Drug discovery revenue is expected to range from $65 million to $75 million.

Benzinga Newsdesk

PRO
Schrodinger Q2 Adj. EPS $0.08 Beats $(0.48) Estimate, Sales $58.889M Beat $47.228M Estimate

Benzinga Newsdesk

PRO
Schrodinger Reaffirms FY And Q2 2026 Financial And Operational Guidance

Benzinga Newsdesk

PRO
Schrodinger Affirms FY2026 Sales Guidance of $273.000M-$293.000M vs $252.752M Est

Schrodinger (NASDAQ:SDGR) affirms FY2026 sales outlook from $273.000 million-$293.000 million to $273.000 million-$293.000 million vs $252.752 million estimate.

Benzinga Newsdesk

PRO
Schrodinger Q1 Adj. EPS $(0.63), Inline, Sales $58.587M Beat $48.002M Estimate

Schrodinger (NASDAQ:SDGR) reported quarterly losses of $(0.63) per share which met the analyst consensus estimate. This is a 1.56 percent increase over losses of $(0.64) per share from the same period last year. The

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved